85
Participants
Start Date
December 31, 2004
Study Completion Date
November 30, 2006
eculizumab
St. James Hospital, Haematology Dept., Cancer Clinical Trial Office, Dublin
Ucl St. Luc, Hematology Department, Brussels
Royal North Shore Hospital, Haematology Department, Saint Leonard
Royal Melbourne Hospital, Dept. of Clinical Haematology & Medical Oncology, Parkville
Princess Alexandra Hospital, Oncology Haematology Radiation Department, Woolloongabba
The Queen Elizabeth Hospital, Haematology/Oncology Department, Woodville South
The Royal Perth Hospital, Dept. of Haematology/Level 2, Perth
NYU Clinical Cancer Center, New York
Memorial Sloan Kettering Cancer Center, New York
Roswell Park Cancer Institute, Buffalo
Presbyterian Medical Center, PENN Comprehensive Hemophilia & Thrombosis Program, Philadelphia
National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda
Johns Hopkins University Medical Center, Baltimore
Duke University Medical Center, Division Cell Therapy, Heme Malignancies Program, Durham
Hospital De La Paz, Servicio de Hematologia, Madrid
Cleveland Clinic Florida, Dept. of Clinical Research, Weston
The Cleveland Clinic Foundation, Cleveland
Indiana University Cancer Pavilion, Indianapolis
Azienda Ospedaliera Universitaria Careggi, Dipartimento di area critica medico-chirurgica, Florence
Mayo Clinic, Division of Hematology, Rochester
Washington University Medical Center, Department of Internal Medicine/Division of Hematology, St Louis
University of Utah, Hematology-BMT Department, Salt Lake City
Norris Comprehensive Cancer Center, Los Angeles
Stanford University Medical Center, Division of Hematology, Stanford
OHSU Center for Hematologic Malignancies, Portland
Hartford Hospital, Cancer Clinical Research Office, Hartford
Massachusetts General Hospital, Boston
Cooper University Hospital, Cooper Cancer Institute, Voorhees Township
University of Alberta, Cross Cancer Institute, Edmonton
London Regional Cancer Centre, Clinical Research Unit Room C3080, London
Hopital Saint-Louis, Centre d'investigation Clinique, Paris
Universitatsklinikum Essen, Zentrum fur Innere Medizin, Essen
Medizinische Hochschule Hannover, Abt. Hamatologie/Onkologie, Zentrum fur Innere Medizin, Hanover
Universitatskliniken des Saarlandes, Innere Medizin 1, Homburg/Saar
Institut fur Klinische Transfusionmedizin und Immungenetik, Abtlg. Transfusionmedizin des Univer. Ulm, Ulm
Ospedale San Martino, Dept. of Hematology, Genova
Ospedale Maggiore di Milano, Divisione di Ematologia, Milan
Universita degli Studi di Napoli, Divisione di Ematologia, Azienda Universitar Policlinico, Napoli
Ospedale San Bortolo, Divisione di Ematologia, Vicenza
UMC St. Radboud, Department of Hematology, Nijmegen
Hospital Clinic i Provincial, Servicio de Hematologia, Barcelona
Hospital Universitario Germans Trias I Pujol, Servicio de Hematologia, Barcelona
Stockholm South Hospital, Division of Hematology, Stockholm
University Hospital, Dept. of Haematology, Uppsala
Kantonsspital Basel, Abteilung fuer Haematologie, Basel
Royal Cornwall Hospital, Truro
Leeds General Infirmary, D Floor Brotherton Wing, Leeds
St. Georges Hospital, Department of Haematology, London
Lead Sponsor
Alexion Pharmaceuticals, Inc.
INDUSTRY